Perspective of the Surviving Sepsis Campaign on the Management of Pediatric Sepsis in the Era of Coronavirus Disease 2019.
Algorithms
Attitude to Health
Betacoronavirus
COVID-19
Child
Coronavirus Infections
/ complications
Critical Care
/ standards
Humans
Multiple Organ Failure
/ etiology
Pandemics
Pediatrics
/ standards
Pneumonia, Viral
/ complications
Practice Guidelines as Topic
Resuscitation
/ standards
SARS-CoV-2
Sepsis
/ etiology
Shock, Septic
/ etiology
Vasoconstrictor Agents
/ therapeutic use
Journal
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
ISSN: 1529-7535
Titre abrégé: Pediatr Crit Care Med
Pays: United States
ID NLM: 100954653
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
5
9
2020
medline:
13
11
2020
entrez:
4
9
2020
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 is a novel cause of organ dysfunction in children, presenting as either coronavirus disease 2019 with sepsis and/or respiratory failure or a hyperinflammatory shock syndrome. Clinicians must now consider these diagnoses when evaluating children for septic shock and sepsis-associated organ dysfunction. The Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-associated Organ Dysfunction in Children provide an appropriate framework for the early recognition and initial resuscitation of children with sepsis or septic shock caused by all pathogens, including severe acute respiratory syndrome coronavirus 2. However, the potential benefits of select adjunctive therapies may differ from non-coronavirus disease 2019 sepsis.
Identifiants
pubmed: 32886460
doi: 10.1097/PCC.0000000000002553
pmc: PMC7597755
pii: 00130478-202011000-00045
doi:
Substances chimiques
Vasoconstrictor Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1031-e1037Subventions
Organisme : NIGMS NIH HHS
ID : K23 GM110496
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
JAMA. 2020 Jul 21;324(3):259-269
pubmed: 32511692
Pediatr Crit Care Med. 2015 Jun;16(5):428-39
pubmed: 25647235
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
JAMA. 2020 May 26;323(20):2085-2086
pubmed: 32293646
Pediatr Crit Care Med. 2014 Jan;15(1):e17-26
pubmed: 24196006
Int Immunopharmacol. 2020 Jul;84:106560
pubmed: 32413736
Lancet Glob Health. 2020 Jul;8(7):e901-e908
pubmed: 32405459
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12526-12527
pubmed: 32398378
J Med Virol. 2020 Jul;92(7):819-823
pubmed: 32232979
Acad Med. 2014 Jan;89(1):114-20
pubmed: 24280846
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
N Engl J Med. 2020 Jul 9;383(2):187-190
pubmed: 32356945
Pediatr Crit Care Med. 2013 Sep;14(7):686-93
pubmed: 23897242
Pediatrics. 1998 Aug;102(2):e19
pubmed: 9685464
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
Pediatr Crit Care Med. 2020 Feb;21(2):e52-e106
pubmed: 32032273
Intensive Care Med. 2020 Feb;46(Suppl 1):10-67
pubmed: 32030529
Lancet Child Adolesc Health. 2020 Jul;4(7):552-554
pubmed: 32437638
JAMA Pediatr. 2020 Sep 01;174(9):868-873
pubmed: 32392288